SCHEMBL3895482

SCHEMBL3895482

C=CCN1C(=O)C(=Cc2ccc(-c3ccc(Cl)cc3)o2)SC1=S

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.80
KMT2A Q03164 3/20 0.80
POLB P06746 2/20 0.80
HIF1AN Q9NWT6 1/20 0.70
MCL1 Q07820 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
PKM P14618 1/20 0.65
STAT3 P40763 1/20 0.58
MAPT P10636 2/20 0.56
MAP3K5 Q99683 5/20 0.55
DUSP3 P51452 1/20 0.55
EIF4E P06730 1/20 0.53
EIF4G1 Q04637 1/20 0.53
ALDH1A1 P00352 1/20 0.53
THRB P10828 1/20 0.53
RECQL P46063 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
EP300 Q09472 1/20 0.52
CREBBP Q92793 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3895477 1.00 MEN1 (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3892083 0.90 MEN1 (0.82) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3892078 0.90 MEN1 (0.82) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3900321 0.89 MEN1 (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3900325 0.89 MEN1 (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL13762527 0.89 POLB (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3126564 0.89 POLB (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3126558 0.89 POLB (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL3126561 0.89 POLB (0.80) MEN1KMT2APOLBHIF1ANMCL1
SCHEMBL12177595 0.89 KMT2A (0.64) MEN1KMT2APOLBHIF1ANMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 WO claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MEN1 1562/4885KMT2A 901/4885POLB 2008/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MEN1 2869/4885KMT2A 1020/4885POLB 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.